HK Stock Market Move | Zhen Health Medical (02697) surges over 16%; organ perfusion system completes six preclinical experiments of ex vivo perfusion supportive treatment using gene-edited pig livers

Zhen Health Medical (02697) surged over 16%, rising 13.63% as of press time to HK$74.6, with a turnover of HK$34.6794 million. On the news front, Zhen Health Medical recently announced that its organ perfusion system research has achieved a major breakthrough, having successfully completed six preclinical experiments of ex vivo cross-perfusion supportive treatment using gene-edited pig livers to assist non-human primate acute liver failure models, setting a record for stable liver function perfusion supportive treatment lasting up to 144 hours, with all six cases exceeding 72 hours. This marks the world's first validation of the long-duration efficacy of this technology. Industry experts stated that the achievement confirms the feasibility and safety of ex vivo perfusion supportive treatment technology using gene-edited pig livers for bridging therapy in liver failure, providing a new technological pathway for treating critically ill liver failure patients. It is reported that the organ perfusion system underpinning this research is a modular organ medical device platform, employing a universal core main unit paired with replaceable specialized tubing, organ chambers, perfusate and other consumables and configuration modules. Without replacing the main unit, it can conduct research applications related to normothermic perfusion preservation and ex vivo life support for multiple organs including liver, kidney, heart, and lung, possessing the technological potential to expand from isolated organ perfusion preservation to ex vivo perfusion supportive treatment research.